Introduction
Colonisation and infection due to multidrug-resistant (MDR) bacteria has become a significant public health concern with both clinical and economic consequences. 1, 2 Surveillance for antimicrobial resistance (AMR) is conducted not only to detect changes or variation in AMR either geographically or over time, but is a vital component of any antimicrobial stewardship programme. 3 Integrated health data on bacterial AMR were obtained from an electronic database of antimicrobial susceptibility testing (AST) results generated by public health laboratories in South Africa. This report was designed to provide information on AMR rates in bacterial pathogens causing both community-associated and healthcare-associated infections and was prepared by the Centre for HAIs, AMR and Mycoses (CHARM) and Surveillance Information Management Unit (SIMU) at the National Institute for Communicable Diseases (NICD) and Corporate Data Warehouse (CDW) at the National Health Laboratory Service (NHLS).
Report objectives and scope
1. To determine the number of cases for each of the following ESKAPE pathogens isolated from blood cultures in 2016: Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter cloacae, and Escherichia coli.
2. To compare AST patterns for each of the ESKAPE pathogens in 2016 with the previous year, 2015.
3. To describe the AST patterns for each of the ESKAPE pathogens by sentinel hospital in 2016.
4. To determine the number of laboratory-confirmed carbapenemase-producing Enterobacteriaceae (CPE) isolated from all specimen types in 2016.
Methods

Data collection and analysis
Data for this report were sourced from the NHLS, CDW. The CDW exists as a national repository for all laboratory tests performed from public sector hospitals in South Africa and contains archived data (demographic and laboratory) from the laboratory information system (LIS), TrakCare. These data were mapped as national, provincial, district and sentinel hospitals by the SIMU at NICD and are available in a dashboard from the NICD website, http://www.nicd.ac.za.
AMR surveillance in the public sector relies on submission of data from the NHLS laboratories that serve academic secondary and tertiary hospitals. 4 Data containing routine AST results for the ESKAPE pathogens were extracted, from January 1, 2016 to December 31, 2016 for 16 sentinel hospitals across South Africa (Table 1) . 4 For the analysis of ESKAPE pathogens, AST results were interpreted in accordance with the Clinical and Laboratory Standards Institute (CLSI) 2016 guidelines and were categorised based on categorical data, susceptible (S) and non-susceptible including intermediate (I) and resistant (R). 5 Due to site-specific differences in testing methodologies and data capture on the LIS, extensive cleaning and recording of data were necessary, which was done within the CDW (Table 2) .
For the analysis of carbapenemase-producing Enterobacteriaceae (CPE), data were obtained from the Antimicrobial Resistance Laboratory (AMRL) at CHARM where carbapenemresistant isolates are referred for phenotypic characterisation, AST and molecular characterisation.
Results
For the purpose of this report, ESKAPE pathogens were categorised as Enterobacteriaceae (Klebsiella pneumoniae, Enterobacter cloacae, and Escherichia coli), non-fermentative Gram-negative bacteria (Acinetobacter baumannii and Pseudomonas aeruginosa) and Gram-positive bacteria (Enterococcus faecalis, Enterococcus faecium and Staphylococcus aureus).
Enterobacteriaceae
Of the 5 265 lactose-fermenting bacteria, 53% (2 783/5 265) were identified as Klebsiella pneumoniae, 35% (1 850/5 265) were identified as Escherichia coli and 12% (632/5265) were identified as Enterobacter cloacae. All three pathogens were reported from all 16 sentinel hospitals in South Africa. Some 21% (1 095/5 265) of all three pathogens were reported from Chris Hani Baragwanath Hospital (Figure 1 ).
Of the panel of antimicrobial agents that were tested, more than 65% of Klebsiella pneumoniae isolates were non-susceptible to third and fourth generation cephalosporins, which is indicative of extended-spectrum beta-lactamase (ESBL) production. In total, 36% (952/2 642) of Klebsiella pneumoniae isolates were non-susceptible to ciprofloxacin, 44% (1 183/2 686) of isolates were non-susceptible to piperacillin/tazobactam and 59% (1 568/2 676) were non-susceptible to gentamicin (Table 3 ). In comparison with 2015, Klebsiella pneumoniae isolates demonstrated higher susceptibility to cefepime (p = 0.65), piperacillin/tazobactam (p = 0.26) and gentamicin in 2016. Although a higher susceptibility was observed for cefepime and piperacillin/ tazobactam in 2016, this was not statistically significant. Overall, antimicrobial susceptibility to carbapenems remained constant over the two-year period ( Figure 2 ). However, high proportions of Klebsiella pneumoniae isolates reported from King Edward VIII Hospital Grey's Hospital, Frere Hospital and Nelson Mandela Academic Hospital/Mthatha Tertiary were shown to display reduced susceptibility to cephalosporins (Table 4) . Less than 30% of Escherichia coli isolates were non-susceptible to third and fourth generation cephalosporins and 30% (530/1760) of isolates were non-susceptible to ciprofloxacin (see Table 3 ). In comparison with 2015, Escherichia coli isolates showed reduced susceptibility in almost all antimicrobial agents ( Figure 2 ). Overall, high proportions of Escherichia coli isolates were shown to be susceptible to carbapenems across all 16 sentinel hospitals (Table 5) .
Antimicrobial susceptibility patterns for Enterobacter cloacae were not reported as data were not available during the preparation of this report.
Non-fermentative gram-negative bacteria
Of the 2 318 non-fermentative Gram-negative bacteria, 71% (1 637/2 318) were identified as Acinetobacter baumannii and 29% (681/2 318) were identified as Pseudomonas aeruginosa. Both pathogens were reported from all 16 sentinel hospitals in South Africa. Approximately 32% (738/2 318) of both pathogens were reported from Chris Hani Baragwanath Hospital ( Figure 3 ).
Of the panel of antimicrobial agents that were tested, more than 80% of Acinetobacter baumannii isolates were non-susceptible to imipenem and meropenem, while 72% (1 140/1 583) and 60% (791/1 320) were non-susceptible to gentamicin and amikacin (Table 6 ). In comparison to 2015, isolates non-susceptible to gentamicin and amikacin increased but, susceptibility to carbapenems and tigecycline remained constant ( Figure 4 (Table 7) . n n n n n n n n n n n n n n n n Approximately 80% and 75% of Pseudomonas aeruginosa isolates were susceptible to cephalosporins and carbapenems (Table 6 ). Antimicrobial susceptibility to imipenem (p = 0.21), cefepime (p = 0.57) and piperacillin/tazobactam (p = 0.39) increased in Pseudomonas aeruginosa; however, this was not statistically significant over the two-year period (Figure 4 ). Almost 50% of
Pseudomonas aeruginosa isolates reported from Tygerberg Hospital showed reduced susceptibility to carbapenems (Table 8) .
Gram-positive bacteria
Of the 3 369 Gram-positive bacteria, 20% (785/3 369) were identified as Enterococcus faecalis, 21% (846/3 369) were identified as n n n n n n n n n n n n n n n n Enterococcus faecium and 59% (2 338/3 369) were identified as Staphylococcus aureus. All three pathogens were reported from all 16 sentinel hospitals in South Africa. Approximately 29% (968/3 369) of all three pathogens were reported from Chris Hani Baragwanath Hospital ( Figure 5 ).
Of the panel of antimicrobial agents that were tested, more than 90% of Enterococcus faecalis and Enterococcus faecium isolates were shown to be susceptible to oxazolidinones and glycopeptides (Table 9 ). In comparison with 2015, AST patterns for the particular antimicrobial agents remained similar in both Enterococcus faecalis and Enterococcus faecium isolates over the two-year period ( Figure 6 ). There were no unusual AST patterns reported for Enterococcus faecalis isolates (Table 10) . Approximately 48% of Enterococcus faecium isolates from Universitas Hospital were shown to be non-susceptible to vancomycin; however, this finding should be interpreted with caution as AST testing for these non-susceptible isolates may not have been confirmed using additional testing (Table 11) .
Approximately 69% of Staphylococcus aureus isolates were susceptible to cloxacillin (Table 9 ). In comparison with 2015, susceptibility to cloxacillin (p = 0.23) increased from 65% to 69%; however, this was not statistically significant ( Figure 6 ). In addition, 50% of Staphylococcus aureus isolates reported from Chris Hani Baragwanath Hospital were shown to be non-susceptible to cloxacillin (Table 12) .
Carbapenemase-producing Enterobacteriaceae
In 2016, AMRL/CHARM identified 1 182 CPE isolates from clinically significant sites (blood and urine were the most common specimen types). Approximately 72% (846/1 182) of CPE isolates were identified as Klebsiella pneumoniae. Approximately 34% (400/1 182) and 63% (741/1 182) of CPE isolates were shown to be positive for bla NDM-1 and bla OXA-48-like encoding genes (Table 13 ). In 2016, CPE isolates encoding for bla OXA-48-like genes were shown to be most prevalent compared with 2015. 6 
Limitations
Interpretation of results
The results of this report should be interpreted with caution. A number of factors might have introduced bias, resulting in either an overestimation or underestimation of AST reporting. 4. Data were omitted for those sentinel hospitals that tested fewer than 30 ESKAPE pathogens for a particular antimicrobial agent.
5. Vancomycin resistance for Staphylococcus aureus requires confirmatory testing, which may not have been available at routine laboratory level. All Staphylococcus aureus isolates that are non-susceptible to vancomycin should be referred to AMRL/CHARM at the NICD.
6. Results for CPE may not be representative as not all CRE isolates are referred to CHARM for CPE confirmatory testing.
Conclusion
In this report, data showed that antimicrobial susceptibility patterns for Klebsiella pneumoniae remained the same over the two-year period. Antimicrobial resistance to third and fourth generation cephalosporins increased for Escherichia coli. Carbapenem resistance in Acinetobacter baumannii is of concern as there are limited antimicrobial options available for treatment of significant infections. Although a large proportion of vancomycin-resistant Enterococcus faecium was reported from Universitas Hospital, these isolates need laboratory confirmation as this may have been an unidentified outbreak. In most pathogens, the AST patterns remained unchanged. There has been a large increase in the number of CPEs identified across South Africa over the two-year period. Enhanced surveillance together with effective antimicrobial stewardship programmes and strict infection control practices are needed to combat AMR in both ESKAPE pathogens and CPEs. The limitations highlighted in this report emphasise the need for continuous improvement in quality of data obtained by electronic surveillance.
Disclaimer
Data are reported as received through the CDW. No demographic, epidemiological, clinical or molecular data were available to distinguish between hospital-associated and community-associated infections.
